OnPoint Analytics

Biosimilars Tracker Last Updated: July 6, 2020

Reference Biologic Drug: EPOGEN/PROCRIT (epoetin alfa, 1989)

# of Biosimilars Approved:
1
Biosimilars Status
% Commercial Lives Covered
Per Unit Price (WAC)
Litigation
Biosimilar Names
Approval Dates
On Market
Biologic
Biosimilars
Unit Type
Biologic
Biosimilars
Discount to Reference
Patent
Antitrust
75%
Per mL (2000 units/mL)
$39.79
RETACRIT
5/15/2018
Y
98%
$26.47
33%
Y

Reference Biologic Drug: NEUPOGEN (filgrastim, 1991)

# of Biosimilars Approved:
2
Biosimilars Status
% Commercial Lives Covered
Per Unit Price (WAC)
Litigation
Biosimilar Names
Approval Dates
On Market
Biologic
Biosimilars
Unit Type
Biologic
Biosimilars
Discount to Reference
Patent
Antitrust
50%
Per mL (comes in 300 mcg/mL & 480 mcg/0.8 mL syringes)
$377.80
ZARXIO
3/6/2015
Y
92%
$329.24
13%
Y
NIVESTYM
7/20/2018
Y
74%
$262.80
30%
Y

Reference Biologic Drug: RITUXAN (rituximab, 1997)

# of Biosimilars Approved:
2
Biosimilars Status
% Commercial Lives Covered
Per Unit Price (WAC)
Litigation
Biosimilar Names
Approval Dates
On Market
Biologic
Biosimilars
Unit Type
Biologic
Biosimilars
Discount to Reference
Patent
Antitrust
86%
10mg (comes in 100mg/10mL & 500mg/50mL vials)
$112.74
TRUXIMA
11/28/2018
Y
44%
$101.47
10%
Y
(settled)
RUXIENCE
7/23/2019
Y
44%
$86.02
24%
N

Reference Biologic Drug: REMICADE (infliximab, 1998)

# of Biosimilars Approved:
4
Biosimilars Status
% Commercial Lives Covered
Per Unit Price (WAC)
Litigation
Biosimilar Names
Approval Dates
On Market
Biologic
Biosimilars
Unit Type
Biologic
Biosimilars
Discount to Reference
Patent
Antitrust
81%
100mg vial
$1,401.38
Y
INFLECTRA
4/5/2016
Y
83%
$1,135.54
19%
Y
RENFLEXIS
4/21/2017
Y
83%
$904.07
35%
Y
IXIFI
12/13/2017
N
N
AVSOLA
12/6/2019
Y
17%
$600.00
57%
N

Reference Biologic Drug: HERCEPTIN (trastuzumab, 1998)

# of Biosimilars Approved:
5
Biosimilars Status
% Commercial Lives Covered
Per Unit Price (WAC)
Litigation
Biosimilar Names
Approval Dates
On Market
Biologic
Biosimilars
Unit Type
Biologic
Biosimilars
Discount to Reference
Patent
Antitrust
85%
150mg vial
$1,870.10
OGIVRI
12/1/2017
Y
71%
$1,589.59
15%
N
HERZUMA
12/14/2018
Y
35%
$1,683.00
10%
Y
(settled)
ONTRUZANT
1/18/2019
Y
35%
$1,589.59
15%
Y
(settled)
TRAZIMERA
3/11/2019
Y
73%
$1,453.32
22%
Y
(settled)
KANJINTI
6/13/2019
Y
83%
$1,584.54
15%
Y

Reference Biologic Drug: ENBREL (etanercept, 1998)

# of Biosimilars Approved:
2
Biosimilars Status
% Commercial Lives Covered
Per Unit Price (WAC)
Litigation
Biosimilar Names
Approval Dates
On Market
Biologic
Biosimilars
Unit Type
Biologic
Biosimilars
Discount to Reference
Patent
Antitrust
99%
40 mg/0.4 mL syringe
$833.54
ERELZI
8/30/2016
N
Y
ETICOVO
4/25/2019
N
Y

Reference Biologic Drug: NEULASTA (pegfilgrastim, 2002)

# of Biosimilars Approved:
3
Biosimilars Status
% Commercial Lives Covered
Per Unit Price (WAC)
Litigation
Biosimilar Names
Approval Dates
On Market
Biologic
Biosimilars
Unit Type
Biologic
Biosimilars
Discount to Reference
Patent
Antitrust
99%
6 mg/per 0.6 mL syringe
$7,477.27
FULPHILA
6/4/2018
Y
86%
$5,010.00
33%
Y
UDENYCA
11/2/2018
Y
98%
$5,010.00
33%
Y
ZIEXTENZO
11/4/2019
Y
61%
$4,710.64
37%
Y

Reference Biologic Drug: HUMIRA (adalizumab, 2002)

# of Biosimilars Approved:
5
Biosimilars Status
% Commercial Lives Covered
Per Unit Price (WAC)
Litigation
Biosimilar Names
Approval Dates
On Market
Biologic
Biosimilars
Unit Type
Biologic
Biosimilars
Discount to Reference
Patent
Antitrust
99%
40mg pen or kit
$3,334.18
Y
AMJEVITA
9/23/2016
N
Y
(settled)
CYLTEZO
8/25/2017
N
Y
(settled)
HYRIMOZ
10/30/2018
N
Y
(settled)
HADLIMA
7/23/2019
N
N
ABRILADA
11/15/2019
N
N

Reference Biologic Drug: AVASTIN (bevacizumab, 2004)

# of Biosimilars Approved:
2
Biosimilars Status
% Commercial Lives Covered
Per Unit Price (WAC)
Litigation
Biosimilar Names
Approval Dates
On Market
Biologic
Biosimilars
Unit Type
Biologic
Biosimilars
Discount to Reference
Patent
Antitrust
85%
Per mL (each mL contains 25mg)
$239.08
MVASI
9/14/2017
Y
83%
$203.22
15%
Y
ZIRABEV
6/27/2019
Y
55%
$184.02
23%
Y
(settled)